Blog

Ryan Schoenfeld: A few topics that continue to stick for me after the 43rd Annual J.P. Morgan Healthcare Conference

Ryan Schoenfeld/themarkfoundation.org

Feb 2, 2025, 02:08

Ryan Schoenfeld: A few topics that continue to stick for me after the 43rd Annual J.P. Morgan Healthcare Conference

Ryan Schoenfeld, Chief Executive Officer at The Mark Foundation for Cancer Research, shared a post on LinkedIn:

“I attended the 43rd Annual J.P. Morgan Healthcare Conference (JPM2025) in San Francisco earlier this month. In addition to enjoying the phenomenal weather as well as being surprised (disturbed?) by the preponderance of driverless cars stalking the streets, I found the trip to be quite informative.

With a couple of weeks now to reflect back, these are a few topics that continue to stick for me:

Molecular glues: With substantial deals happening both late last year and just following the conference this month, there is clearly strong interest continuing from the pharmaceutical industry. I spoke with a number of companies working in this space and am optimistic that this therapeutic modality will deliver innovative therapeutics to treat cancer.

Antibody-drug conjugates: Last year at JPM 2024, ADCs seemed to be the major topic everyone was talking about, almost to the point of overload.

This year, however, the conversation felt a little quieter. The challenges in developing this therapeutic modality are significant, but there is also much potential to bring benefit to cancer patients. It will be interesting to see how the momentum swings in 2025.

Artificial intelligence: Conversations around AI continue to focus heavily on data – who owns it and how much is really needed to drive new insights. Specifically, the question of how to bridge the gap between academia and industry in data sharing remains critical.

This is an area where organizations like The Mark Foundation for Cancer Research can play a pivotal role, helping to foster collaboration and accelerate progress.

Partnership: I met with collaborators across academia, venture, pharma, and biotech – energized by the possibilities that lie ahead.

The key takeaway: tackling the toughest cancer research challenges, from early detection to new therapeutics, requires working together across sectors. And as we look forward to another year, the opportunities for collaboration and innovation feel more promising than ever.”

More posts featuring Ryan Schoenfeld.